Back to top
more

Johnson & Johnson (JNJ)

(Delayed Data from NYSE)

$155.04 USD

155.04
7,145,777

-0.43 (-0.28%)

Updated Nov 11, 2024 04:00 PM ET

After-Market: $155.14 +0.10 (0.06%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value C Growth C Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 23% (57 out of 250)

Industry: Large Cap Pharmaceuticals

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Should You Invest in the Fidelity MSCI Health Care Index ETF (FHLC)?

by Zacks Equity Research

Sector ETF report for FHLC

Should iShares Core High Dividend ETF (HDV) Be on Your Investing Radar?

by Zacks Equity Research

Style Box ETF report for HDV

Should You Invest in the iShares U.S. Pharmaceuticals ETF (IHE)?

by Zacks Equity Research

Sector ETF report for IHE

Is Vanguard High Dividend Yield ETF (VYM) a Strong ETF Right Now?

by Zacks Equity Research

Smart Beta ETF report for VYM

J&J (JNJ) Seeks EU Nod for Rybrevant for First-Line NSCLC

by Zacks Equity Research

J&J (JNJ) files an application in Europe seeking expanded approval for Rybrevant as a first-line combination treatment in patients with advanced or metastatic EGFR exon 20 insertion mutation-positive NSCLC.

Will Johnson & Johnson (JNJ) Beat Estimates Again in Its Next Earnings Report?

by Zacks Equity Research

Johnson & Johnson (JNJ) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Investors Heavily Search Johnson & Johnson (JNJ): Here is What You Need to Know

by Zacks Equity Research

Johnson & Johnson (JNJ) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

Sanofi (SNY) Inks Deal With J&J to Develop E. coli Vaccine

by Zacks Equity Research

Per the terms of the deal, Sanofi (SNY) and J&J will co-fund current and future R&D costs to develop a potential first-in-class vaccine against extraintestinal pathogenic E. coli.

Johnson & Johnson (JNJ) Stock Sinks As Market Gains: What You Should Know

by Zacks Equity Research

Johnson & Johnson (JNJ) closed at $155.15 in the latest trading session, marking a -0.39% move from the prior day.

J&J's (JNJ) Rybrevant Combo Meets Primary Goal in NSCLC Study

by Zacks Equity Research

J&J (JNJ) meets the primary goal in the late-stage study of the combination therapy of Rybrevant and lazertinib against Tagrisso for EGFR-mutated first-line NSCLC.

The Zacks Analyst Blog Highlights AbbVie, Lilly, Sanofi, Merck and J&J

by Zacks Equity Research

AbbVie, Lilly, Sanofi, Merck and J&J are included in this Analyst Blog.

Kinjel Shah headshot

Pharma Stock Roundup: FDA and EMA Regulatory Updates for ABBV, LLY, SNY & MRK's Drugs

by Kinjel Shah

The European Commission approves AbbVie's (ABBV) Tepkinly (epcoritamab) for DLBCL. FDA approves Lilly's (LLY) Jardiance for chronic kidney disease.

Johnson & Johnson (JNJ) Stock Moves -0.77%: What You Should Know

by Zacks Equity Research

Johnson & Johnson (JNJ) closed the most recent trading day at $159.02, moving -0.77% from the previous trading session.

Novartis' (NVS) Sandoz Gets EC Nod for Tysabri's Biosimilar

by Zacks Equity Research

Novartis' (NVS) Sandoz broadens its biosimilar portfolio with Tyruko's approval, a biosimilar of the multiple sclerosis drug Tysabri in the EU.

Should You Invest in the Invesco Pharmaceuticals ETF (PJP)?

by Zacks Equity Research

Sector ETF report for PJP

Here is What to Know Beyond Why Johnson & Johnson (JNJ) is a Trending Stock

by Zacks Equity Research

Zacks.com users have recently been watching Johnson & Johnson (JNJ) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

Should You Invest in the iShares U.S. Healthcare ETF (IYH)?

by Zacks Equity Research

Sector ETF report for IYH

Johnson & Johnson (JNJ) Stock Moves -0.17%: What You Should Know

by Zacks Equity Research

Johnson & Johnson (JNJ) closed the most recent trading day at $162.20, moving -0.17% from the previous trading session.

The Zacks Analyst Blog Highlights Meta Platforms, Walmart, Johnson & Johnson, Pfizer and Morgan Stanley

by Zacks Equity Research

Meta Platforms, Walmart, Johnson & Johnson, Pfizer and Morgan Stanley are part of the Zacks top Analyst Blog.

Should You Invest in the Health Care Select Sector SPDR ETF (XLV)?

by Zacks Equity Research

Sector ETF report for XLV

Is Franklin U.S. Low Volatility High Dividend Index ETF (LVHD) a Strong ETF Right Now?

by Zacks Equity Research

Smart Beta ETF report for LVHD

Sheraz Mian headshot

Top Analyst Reports for Meta Platforms, Walmart & Johnson & Johnson

by Sheraz Mian

Today's Research Daily features new research reports on 16 major stocks, including Meta Platforms, Inc. (META), Walmart Inc. (WMT) and Johnson & Johnson (JNJ).

Should iShares Russell Top 200 Value ETF (IWX) Be on Your Investing Radar?

by Zacks Equity Research

Style Box ETF report for IWX

Johnson & Johnson (JNJ) Outpaces Stock Market Gains: What You Should Know

by Zacks Equity Research

In the latest trading session, Johnson & Johnson (JNJ) closed at $163.99, marking a +0.25% move from the previous day.

AbbVie's (ABBV) Skyrizi Crohn's Disease Study Meets Goals

by Zacks Equity Research

AbbVie's (ABBV) Skyrizi met both primary endpoints of non-inferiority for clinical remission at week 24 and superiority of endoscopic remission at week 48 versus J&J's Stelara in a head-to-head study.